Patient decision aids for patients with differentiated thyroid carcinoma: development process and alpha and beta testing
BackgroundPatient decision aids (PtDAs) are structured clinical tools that facilitate shared decision-making. Two important treatment decisions for patients with differentiated thyroid cancer (DTC), which could benefit from PtDAs, are as follows (1): the extent of surgery decision in patients with l...
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-05-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2023.1162537/full |
| _version_ | 1797815477852962816 |
|---|---|
| author | Anna Koot Anna Koot Rosella Hermens Petronella Ottevanger Romana Netea-Maier Peep Stalmeier the COMBO study group Marieke Snel Noortje van der Kleij-Corssmit Johannes Bonenkamp Koen Dreijerink Evelien van Dam Grard Nieuwenhuijzen Mariel Keemers Lieke Welling Iris van der Ploeg Sanne Engelen Danielle Dercks Frans Geenen |
| author_facet | Anna Koot Anna Koot Rosella Hermens Petronella Ottevanger Romana Netea-Maier Peep Stalmeier the COMBO study group Marieke Snel Noortje van der Kleij-Corssmit Johannes Bonenkamp Koen Dreijerink Evelien van Dam Grard Nieuwenhuijzen Mariel Keemers Lieke Welling Iris van der Ploeg Sanne Engelen Danielle Dercks Frans Geenen |
| author_sort | Anna Koot |
| collection | DOAJ |
| description | BackgroundPatient decision aids (PtDAs) are structured clinical tools that facilitate shared decision-making. Two important treatment decisions for patients with differentiated thyroid cancer (DTC), which could benefit from PtDAs, are as follows (1): the extent of surgery decision in patients with low-risk DTC and (2) the decision to start or delay starting the treatment with tyrosine kinase inhibitors (TKIs) in patients with advanced tumors.Material and methodsPtDAs for these two decisions were developed using the International Patient Decision Aids Standards (IPDAS) quality criteria in an iterative process of prototype development via alpha and beta testing by patients and physicians. The information content of the PtDAs was based on the available literature, current guidelines, and patient’s needs, preferences, and values.ResultsThe web-based PtDAs underwent two rounds of alpha testing, revisions, and beta testing. The PtDAs have the same structure, consisting of six steps: a general introduction, information about the treatment options, comparing the treatment options, knowledge questions, a values clarification exercise, and saving the information. The alpha testing (n = 8 patients, n = 10 physicians) showed that the PtDAs were highly acceptable and usable for decision-making. Results of the beta testing in 20 patients showed that two patients did not use the PtDA; the other 18 patients found that the PtDAs were readable (n = 17) and helpful (n = 14) for decision-making. All patients recommend using the PtDAs.ConclusionsEvidence-based PtDAs were created for patients with DTC for two different treatment decisions. Our final version was judged to be clear, balanced, and helpful in decision-making. |
| first_indexed | 2024-03-13T08:23:19Z |
| format | Article |
| id | doaj.art-fe514fc99b114bbb8f803ccac5c1afb8 |
| institution | Directory Open Access Journal |
| issn | 1664-2392 |
| language | English |
| last_indexed | 2024-03-13T08:23:19Z |
| publishDate | 2023-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Endocrinology |
| spelling | doaj.art-fe514fc99b114bbb8f803ccac5c1afb82023-05-31T05:07:14ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922023-05-011410.3389/fendo.2023.11625371162537Patient decision aids for patients with differentiated thyroid carcinoma: development process and alpha and beta testingAnna Koot0Anna Koot1Rosella Hermens2Petronella Ottevanger3Romana Netea-Maier4Peep Stalmeier5the COMBO study groupMarieke SnelNoortje van der Kleij-CorssmitJohannes BonenkampKoen DreijerinkEvelien van DamGrard NieuwenhuijzenMariel KeemersLieke WellingIris van der PloegSanne EngelenDanielle DercksFrans GeenenRadboud Institute for Health Sciences, Department for Health Evidence, Radboud University Medical Center, Nijmegen, NetherlandsDepartment of Internal Medicine, Division of Endocrinology, Radboud University Medical Center, Nijmegen, NetherlandsRadboud Institute for Health Sciences, Scientific Institute for Quality of Healthcare (IQ Healthcare), Radboud University Medical Center, Nijmegen, NetherlandsDepartment of Internal Medicine, Division of Oncology, Radboud University Medical Center, Nijmegen, NetherlandsDepartment of Internal Medicine, Division of Endocrinology, Radboud University Medical Center, Nijmegen, NetherlandsRadboud Institute for Health Sciences, Department for Health Evidence, Radboud University Medical Center, Nijmegen, NetherlandsBackgroundPatient decision aids (PtDAs) are structured clinical tools that facilitate shared decision-making. Two important treatment decisions for patients with differentiated thyroid cancer (DTC), which could benefit from PtDAs, are as follows (1): the extent of surgery decision in patients with low-risk DTC and (2) the decision to start or delay starting the treatment with tyrosine kinase inhibitors (TKIs) in patients with advanced tumors.Material and methodsPtDAs for these two decisions were developed using the International Patient Decision Aids Standards (IPDAS) quality criteria in an iterative process of prototype development via alpha and beta testing by patients and physicians. The information content of the PtDAs was based on the available literature, current guidelines, and patient’s needs, preferences, and values.ResultsThe web-based PtDAs underwent two rounds of alpha testing, revisions, and beta testing. The PtDAs have the same structure, consisting of six steps: a general introduction, information about the treatment options, comparing the treatment options, knowledge questions, a values clarification exercise, and saving the information. The alpha testing (n = 8 patients, n = 10 physicians) showed that the PtDAs were highly acceptable and usable for decision-making. Results of the beta testing in 20 patients showed that two patients did not use the PtDA; the other 18 patients found that the PtDAs were readable (n = 17) and helpful (n = 14) for decision-making. All patients recommend using the PtDAs.ConclusionsEvidence-based PtDAs were created for patients with DTC for two different treatment decisions. Our final version was judged to be clear, balanced, and helpful in decision-making.https://www.frontiersin.org/articles/10.3389/fendo.2023.1162537/fullthyroid cancershared decision makingsurgerytyrosine kinase inhibitordecision aid |
| spellingShingle | Anna Koot Anna Koot Rosella Hermens Petronella Ottevanger Romana Netea-Maier Peep Stalmeier the COMBO study group Marieke Snel Noortje van der Kleij-Corssmit Johannes Bonenkamp Koen Dreijerink Evelien van Dam Grard Nieuwenhuijzen Mariel Keemers Lieke Welling Iris van der Ploeg Sanne Engelen Danielle Dercks Frans Geenen Patient decision aids for patients with differentiated thyroid carcinoma: development process and alpha and beta testing Frontiers in Endocrinology thyroid cancer shared decision making surgery tyrosine kinase inhibitor decision aid |
| title | Patient decision aids for patients with differentiated thyroid carcinoma: development process and alpha and beta testing |
| title_full | Patient decision aids for patients with differentiated thyroid carcinoma: development process and alpha and beta testing |
| title_fullStr | Patient decision aids for patients with differentiated thyroid carcinoma: development process and alpha and beta testing |
| title_full_unstemmed | Patient decision aids for patients with differentiated thyroid carcinoma: development process and alpha and beta testing |
| title_short | Patient decision aids for patients with differentiated thyroid carcinoma: development process and alpha and beta testing |
| title_sort | patient decision aids for patients with differentiated thyroid carcinoma development process and alpha and beta testing |
| topic | thyroid cancer shared decision making surgery tyrosine kinase inhibitor decision aid |
| url | https://www.frontiersin.org/articles/10.3389/fendo.2023.1162537/full |
| work_keys_str_mv | AT annakoot patientdecisionaidsforpatientswithdifferentiatedthyroidcarcinomadevelopmentprocessandalphaandbetatesting AT annakoot patientdecisionaidsforpatientswithdifferentiatedthyroidcarcinomadevelopmentprocessandalphaandbetatesting AT rosellahermens patientdecisionaidsforpatientswithdifferentiatedthyroidcarcinomadevelopmentprocessandalphaandbetatesting AT petronellaottevanger patientdecisionaidsforpatientswithdifferentiatedthyroidcarcinomadevelopmentprocessandalphaandbetatesting AT romananeteamaier patientdecisionaidsforpatientswithdifferentiatedthyroidcarcinomadevelopmentprocessandalphaandbetatesting AT peepstalmeier patientdecisionaidsforpatientswithdifferentiatedthyroidcarcinomadevelopmentprocessandalphaandbetatesting AT thecombostudygroup patientdecisionaidsforpatientswithdifferentiatedthyroidcarcinomadevelopmentprocessandalphaandbetatesting AT mariekesnel patientdecisionaidsforpatientswithdifferentiatedthyroidcarcinomadevelopmentprocessandalphaandbetatesting AT noortjevanderkleijcorssmit patientdecisionaidsforpatientswithdifferentiatedthyroidcarcinomadevelopmentprocessandalphaandbetatesting AT johannesbonenkamp patientdecisionaidsforpatientswithdifferentiatedthyroidcarcinomadevelopmentprocessandalphaandbetatesting AT koendreijerink patientdecisionaidsforpatientswithdifferentiatedthyroidcarcinomadevelopmentprocessandalphaandbetatesting AT evelienvandam patientdecisionaidsforpatientswithdifferentiatedthyroidcarcinomadevelopmentprocessandalphaandbetatesting AT grardnieuwenhuijzen patientdecisionaidsforpatientswithdifferentiatedthyroidcarcinomadevelopmentprocessandalphaandbetatesting AT marielkeemers patientdecisionaidsforpatientswithdifferentiatedthyroidcarcinomadevelopmentprocessandalphaandbetatesting AT liekewelling patientdecisionaidsforpatientswithdifferentiatedthyroidcarcinomadevelopmentprocessandalphaandbetatesting AT irisvanderploeg patientdecisionaidsforpatientswithdifferentiatedthyroidcarcinomadevelopmentprocessandalphaandbetatesting AT sanneengelen patientdecisionaidsforpatientswithdifferentiatedthyroidcarcinomadevelopmentprocessandalphaandbetatesting AT danielledercks patientdecisionaidsforpatientswithdifferentiatedthyroidcarcinomadevelopmentprocessandalphaandbetatesting AT fransgeenen patientdecisionaidsforpatientswithdifferentiatedthyroidcarcinomadevelopmentprocessandalphaandbetatesting |